How should we manage a patient with a positive PPD and prior BCG vaccination? by Rowland, Kathleen et al.
718 VOL 55, NO 8 / AUGUST 2006  THE JOURNAL OF FAMILY PRACTICE
From the 
Family Physicians
Inquiries Network
CLINICAL INQUIRIES
Kathleen Rowland, MD,
Richard Guthmann, MD
University of Illinois at
Chicago/Advocate Illinois
Masonic Family Medicine
Residency
Barbara Jamieson, MLS
Medical College of Wisconsin,
Milwaukee
How should we manage a patient 
with a positive PPD 
and prior BCG vaccination?
E V I D E N C E - B A S E D A N S W E R
C L I N I C A L C O M M E N TA R Y
z Evidence summary
In areas where tuberculosis is prevalent,
the World Health Organization recom-
mends BCG vaccination at birth, without
Prior bacille Calmette-Guérin (BCG) vacci-
nation increases the likelihood of a positive
tuberculosis (TB) 5TU purified protein deriv-
ative (PPD) skin test. The PPD response fol-
lowing BCG vaccine varies with age at vac-
cination, number of years since the BCG
vaccination, number of times vaccinated,
and number of PPDs performed. An indura-
tion of greater than 14 mm is unlikely to be
due to prior BCG vaccination (strength of
recommendation [SOR]: A, based on meta-
analysis of validation cohort studies).
The variable reaction after BCG vaccina-
tion, along with the desire to detect all
cases of TB, has led to recommendations
that all patients with a positive PPD test be
treated as true positives. These patients
should undergo chest radiography and
appropriate treatment, regardless of history
of BCG vaccine (SOR: B, extrapolation from
level 1 study).
A recently developed alternative is the
interferon-gamma assay (QuantiFERON-TB
Gold test), which may be used in place of,
or in addition to, the PPD skin test for
patients who are known to have received a
BCG vaccine (SOR: B, extrapolation from a
validation cohort study).
Disregard history of BCG immunization
when evaluating positive PPDs 
among immigrants
When I was in residency in Seattle, the
experts at the King County TB clinic
advised disregarding the history of BCG
immunization when evaluating positive
PPDs among immigrants. The authors of
this review provide evidence confirming this
policy. The only new option for helping your
patients in weighing the pros and cons of
chemoprophylaxis for latent TB is the new
interferon-gamma assay. While 3 times the
cost of a PPD, it is a reasonable option for
patients who want more specific evidence
of latent infection before taking 6 to 9
months of a potentially toxic therapy.
I can think of many situations where the 
specificity of this test may have persuaded
some patients to undertake treatment and
spared others the risks and inconvenience
of isoniazid.
Drew Malloy, MD
University of California Santa Cruz Student Health
Service, Santa Cruz, Calif
booster doses, to prevent childhood com-
plications of TB infection;1 however, the
vaccine’s efficacy is known to be inconsis-
tent. Though BCG vaccine given at birth
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can decrease the risk of miliary TB and 
TB meningitis among children, estimates
of its effectiveness in preventing adult 
pulmonary TB range widely from 0% to
80%.1
Though prior BCG vaccination
increases the risk of a reactive PPD, this
effect is also known to be inconsistent. A
2002 meta-analysis showed that the per-
son’s age at the time of their BCG vaccina-
tion and the years since vaccination influ-
ence the relative risk of a positive PPD
(TABLE). The highest relative risk of a pos-
itive PPD occurred among patients who
received BCG vaccination after infancy
and within 15 years of the PPD testing.
This same meta-analysis also examined the
significance of the size of the PPD
response; a subset of 4 studies showed that
equal proportions of BCG vaccinated and
unvaccinated patients had indurations of
14 mm or more.2
BCG vaccine may confound PPD read-
ings, but several studies indicate that PPD
can still be a useful screening tool for
tuberculosis infection after vaccination. A
Brazilian case-control study found that
reactions by those BCG recipients later
exposed to TB were significantly greater
than those with no TB exposure.3 The
study noted that 47.5% of exposed chil-
dren (defined as those with a household
contact) had PPD readings of >10 mm,
compared with just 3.6% of control chil-
dren. In a Quebec cohort of 1198 foreign-
born children and young adults, prior
BCG vaccination could account for 50%
of PPDs with induration of 5 to 9 mm, but
only 4% of reactions 10 mm or greater.
This study also showed that patients from
countries with a high or moderate inci-
dence of TB were more likely to have reac-
tive PPDs than those from countries of low
incidence, suggesting that exposure to TB
accounts for some of the positive PPDs.4
Where it is available, the Quanti-
FERON-TB Gold test may be used in place
of, or in addition to, the PPD for patients
who are known to have received a BCG
vaccine. This blood test detects interferon-
gamma in the serum of people sensitized to
Mycobacterium tuberculosis. Because the
test is specific to proteins found in M
tuberculosis, there is no cross-reactivity
with BCG. A Japanese study of 216 BCG-
vaccinated individuals showed interferon-
gamma assays to be 98.1% specific. The
same study reported 89.0% sensitivity for
the combination of 2 interferon-gamma
assays among 118 TB culture-confirmed
individuals.5 A published report estimated
the cost to the health care system per
patient tested by a single interferon-
gamma release assay as $33.67, compared
with approximately $11 for PPD testing.6
Recommendations from others
While the US Preventive Services Task
Force (USPSTF) does not make a specific
recommendation regarding PPD readings
after BCG vaccine, it does recommend
screening high-risk populations. The 
USPSTF further notes that reactions >10
mm should not be attributed to prior BCG
vaccine.7
The interferon-
gamma assay,
though expensive,
has no cross-
reactivity with BCG
FAST TRACK
T A B L E
RECEIVED
BCG NO BCG RR (95% CI)
Given in infancy
Timing of PPD unspecified 22.3% 19.2% 1.16 (1.09–1.23)
PPD less than 15 yrs 12.6% 5.2% 2.4 (2.00–2.97)
since BCG
PPD more than 15 yrs 47.2% 41.0% 1.2 (1.09–1.22)
since BCG
Given after infancy
Timing of PPD unspecified 35.6% 17.4% 2.08 (1.89–2.21)
PPD less than 15 yrs 29.1% 2.9% 10 (5.29–18.99)
since BCG
PPD more than 15 yrs 37.6% 47.8% 0.8 (0.74–0.85)
since BCG
PPD, purified protein derivative; BCG, bacille Calmette-Guérin; RR, relative risk; 
CI, confidence interval
PPD reactions >10 mm when BCG was given 
during and after infancy
 
The Centers for Disease Control and
Prevention (CDC) and American Thoracic
Society joint statement recommends
against altering guidelines for testing and
interpretation among BCG recipients.8 In
2005, the CDC recommended the
QuantiFERON-TB Gold test be used
under the same indications as the PPD,
noting its potential benefit among those
previously immunized with BCG.9
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